A "Prime-Pull" Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice by Tregoning, JS et al.
A ‘‘Prime-Pull’’ Vaccine Strategy Has a Modest Effect on
Local and Systemic Antibody Responses to HIV gp140 in
Mice
John S. Tregoning., Viviana Buffa.¤a, Anna Oszmiana¤b, Katja Klein, Adam A. Walters¤c,
Robin J. Shattock*
Mucosal Infection & Immunity Group, Section of Infectious Diseases, Imperial College London, London, United Kingdom
Abstract
One potential strategy for the prevention of HIV infection is to induce virus specific mucosal antibody that can act as an
immune barrier to prevent transmission. The mucosal application of chemokines after immunisation, termed ‘‘prime-pull’’,
has been shown to recruit T cells to mucosal sites. We wished to determine whether this strategy could be used to increase
B cells and antibody in the vaginal mucosa following immunisation with an HIV antigen. BALB/c mice were immunised
intranasally with trimeric gp140 prior to vaginal application of the chemokine CCL28 or the synthetic TLR4 ligand MPLA,
without antigen six days later. There was no increase in vaginal IgA, IgG or B cells following the application of CCL28,
however vaginal application of MPLA led to a significant boost in antigen specific vaginal IgA. Follow up studies to
investigate the effect of the timing of the ‘‘pull’’ stimulation demonstrated that when given 14 days after the initial
immunisation MPLA significantly increased systemic antibody responses. We speculate that this may be due to residual
inflammation prior to re-immunisation. Overall we conclude that in contrast to the previously observed effect on T cells, the
use of ‘‘prime-pull’’ has only a modest effect on B cells and antibody.
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Introduction
One strategy for HIV vaccine development is to generate a local
immune barrier at the site of infection [1]. Evidence demonstrat-
ing that in the majority of heterosexual transmission cases,
infection is caused by a single founder virion [2] suggests that
this strategy could be effective. Whilst mucosal lymphoid cells –
including T cells, intra-epithelial lymphocytes and innate lym-
phoid cells can play a role in local protection, antibody is a potent
tool to provide the local immune barrier [3]. The ideal result of
HIV vaccination would be the generation of broadly neutralising
antibodies at the site of infection [4], but virus specific IgA could
play a role in the immune barrier due to its immune exclusion
function, even if it is not directly neutralising [5].
We have previously observed that mucosal immunisation can
induce local antibody responses to trimeric HIV envelope protein
gp140 [6–8]. One possible approach to increase mucosal responses
is to use a ‘‘prime-pull’’ strategy, where lymphocytes are redirected
to local sites using chemokines following immunisation. This
strategy has been demonstrated to be effective for the recruitment
of both CD4 and CD8 cells to the vagina using CCL9 and CCL10
[9] and regulatory CD4 T cells to the lungs using CCL17 and
CCL22 [10]. We wished to determine whether a similar approach
could be used to recruit B cells to the vagina following
immunisation.
B cells are attracted to a range of factors, including the
chemokines CCL19, CCL21, CCL28, CCL25, the integrins a4b1,
and a4b7 and the cytokines BAFF, APRIL and TSLP [11]. We
have previously looked at the effect of BAFF, APRIL and TSLP as
mucosal adjuvants [12] and observed that only TSLP boosted the
antibody response to antigen. The chemokine receptors CCR7
and to some extent CXCR4, are required for naı¨ve B cell entry
into lymph nodes and migration to the T cell zones [13], and
antigen exposure increases CCR7 expression and the chemokine
CCL19 is effective when used as an adjuvant [14]. But we are
aiming to recruit plasmablasts and/or plasma cells – which are
CCR7 negative. The chemokine CCL28 attracts B cells to the
mucosa, particularly IgA producing cells [15]. CCL28 is expressed
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e80559
by mucosal epithelia at the bronchi, salivary gland, mammary
glands and small intestine and when co-administered with HIV-
VLP, CCL28 boosted the antibody response [16]. One limitation
of translating the chemokine strategy to a vaccine is that because
chemokines are proteins, they are expensive to manufacture,
therefore we wished to determine whether Toll like receptor (TLR)
ligands which have been used as mucosal adjuvants [17] can be
used in the ‘‘prime-pull’’ approach. One such agent is monopho-
sphoryl lipid A (MPLA) a non-toxic derivative of LPS, the first
TLR ligand approved for human use for its safety and effectiveness
as an adjuvant [18].
In this study we investigated the use of the chemokine CCL28
and TLR ligand MPLA as boost agents (without antigen) in a
‘‘prime-pull’’ regime following either mucosal or systemic immu-
nisation with the HIV envelope protein gp140. We observed that
the vaginal administration of MPLA alone after immunisation but
not CCL28 led to an increase in vaginal IgA, systemic IgA and
IgG and antigen specific B cells in the female genital tract. The
timing of boost was important, with a greater response seen when
‘‘pull’’ stimulation was given 7 or 14 days after immunisation
compared to when it is given on the day of immunisation.
Interestingly mucosal administration of MPLA alone significantly
increased systemic antibody responses to subsequent immunisa-
tions. Here we show that it is possible to increase the vaginal IgA
using a ‘‘prime-pull’’ strategy, but the increase in antibody titre
was modest and unsustained.
Materials and Methods
Animals, Antigen and adjuvants
Female BALB/c mice, 6–8 week old, were obtained from
Harlan Olac Ltd (Bevil’s Hill, UK). All procedures were
performed in accordance with the United Kingdom’s Home
Office standards under the Animals Scientific Procedures Act,
1986, and approved by the Ethical Review Boards at Imperial
College London and at St George’s University of London. In the
timecourse and comparison of TLR ligands studies, the same
group of control animals were used to reduce animal usage. A
clade C HIV-1 envelope clone p97CN54 was originally isolated
from a Chinese patient [19] and was made available by H. Wolf
and R. Wagner, University of Regensburg, Germany. Trimeric
gp140 (gp120 plus the external domain (ED) of gp140), designated
CN54 gp140, was produced as a recombinant product in CHO
cells and manufactured to GMP specification by Polymun
Scientific, Vienna, Austria. The TLR ligand FSL-1 (TLR2/6)
was purchased from Invivogen, monophosphoryl Lipid A (MPLA,
TLR4) from Sigma and CpG (TLR9) from MWG. Recombinant
murine CCL28 was purchased from R&D systems.
Immunisation protocol
Mice were immunized 3 times with 3 weeks interval, with 10 mg
gp140 and 10mg MPLA. The gp140/MPLA formulation was
either administered intranasally in a total volume of 20ml or
subcutaneously in a volume of 50ml. At 0, 7, or 14 days after
immunisation, animals received an intravaginal ‘‘pull’’ stimulation
of 10mg of MPLA, CCL28, FSL-1 or CpG in a volume of 20ml.
Sample and tissue collection
Serum and mucosal samples were obtained at various intervals
before or after immunisation as described previously [12].
The mouse genital tract, including vagina, uterus, oviducts, and
ovaries were dissected from the animal, and placed in cold
complete medium (RPMI-1640 supplemented with 10% fetal
bovine serum (FBS), 2 mM glutamine, 10 mM HEPES, 100 IU/
ml penicillin, 100mg/ml streptomycin, and 10mg/ml gentamycin).
The tissue was finely cut with a scalpel, washed with complete
medium and digested at 37uC for 1 h on a shaker with 5 ml of
serum-free RPMI-1640 medium that contained 2 mg Collagenase
Dispase and 0.1 mg/ml DNaseI (Roche Diagnostics). The
digested tissue was spun and the cell pellet washed twice in CM.
The lymphoid cell population was separated from the stromal cells
by density gradient centrifugation (Lympholyte, Cedarlane Lab-
oratories).
Detection of antigen-specific antibody responses by
ELISA
MaxiSorp 96-well plates were coated overnight with 1.0 mg/ml
HIV-1 gp140 in PBS. Plates were blocked for 1 h at 37uC with
1% BSA in PBS. Serially diluted samples were incubated for 1 h at
37uC. Bound IgG was detected by incubation for 1 h at 37uC with
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG
(AbD Serotec, UK) and IgA was detected with biotin-conjugated
goat anti-mouse IgA (AbD Serotec, UK). For IgA detection, plates
were incubated with Streptavidin-HRP (R&D Systems) for 1 h at
37uC. Plates were developed using tetramethylbenzidine (TMB)
substrate. The reaction was stopped with stop solution (1N H2SO4)
and read at 450 nm. Reciprocal endpoint titres were calculated by
using GraphPad Prism 4 using a cut-off value at OD450 of 0.1 for
all samples.
ELISPOT
Cells from genital tract were assessed for the presence of gp140-
specific IgG and IgA antibody secreting cells (ASC). Cells from
genital tract were assessed immediately after isolation. ELISPOT
assays were performed using a commercial kit from MABTECH
(Nacka Strand, Sweden) following the manufacturer’s recommen-
dations. The spots were counted using the AID ELISPOT reader
ELR03 (Autoimmune Diagnostika).
Statistical Analysis
Analyses were performed using GraphPad Prism, version 4.00
(GraphPad Software). Statistical differences between groups were
calculated using one-way analysis of variance (ANOVA) with
appropriate post tests to measure significance between pairs of
groups.
Results
We wished to determine whether we could recruit B cells into
the vaginal mucosa following immunisation using a ‘‘prime-pull’’
strategy. Mice were immunised three times intranasally with the
model HIV antigen gp140 together with MPLA as a mucosal
adjuvant, which we have previously shown to increase systemic
and local responses to antigen [17]. Six days after each
immunisation or ‘‘prime’’, mice received a vaginal administration
of 10mg MPLA, 10mg CCL28 or PBS control, without antigen
designed to provide a chemotactic ‘‘pull’’ to coincide with release
of antigen specific plasmablasts into the systemic circulation. Thus
each animal received three rounds of ‘‘prime’’ immunisation
followed by vaginal ‘‘pull’’ stimulation (Fig 1A). Anti-gp140 IgG
and IgA were measured in sera and vaginal washes collected on
days 34 – after 2nd intravaginal ‘‘pull’’ dose, 42 – before the 3rd
intravaginal ‘‘pull’’ dose and 56 after the 3rd intravaginal dose.
‘‘Pull’’ stimulation with CCL28 had no significant effect on
antibody specific IgG or IgA in serum or vaginal lavage compared
to PBS treated animals. However, mice that received intravaginal
MPLA had significantly greater levels of vaginal IgA levels after
‘‘pull’’ stimulation on day 34 (Fig 1B, p,0.01). Although these
"Prime-Pull" Vaccination to Boost Mucosal Antibody
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responses appeared to wane after the second administration of
MPLA, levels rose again after the third intravaginal dose (day 56,
p,0.01). There was no significant difference in mucosal IgG after
MPLA delivery (Fig 1C). The MPLA treated group also had
significantly more sera IgA (Fig 1D, p,0.05) on days 42 and 56
and sera IgG on day 56 compared to the PBS treated animals
(Fig 1E, p,0.01). Total and antigen specific B cells were measured
in the female genital tract by ELISPOT, due to the low number of
cells collected, samples had to be pooled for analysis. A trend of
increased B cell numbers was observed in the vaginas of MPLA
treated mice – both total and antigen specific (Fig 1F).
Having observed an increase in vaginal responses following
MPLA treatment of intranasally immunised mice, we wished to
determine whether it was possible to ‘‘pull’’ cells into the mucosa
following a systemic immunisation. This would be advantageous as
the initial vaccination could be delivered using standard method-
ology, improving the practicality of the approach. As with the
intranasal experiment, mice were immunised three times subcu-
taneously with gp140 and MPLA, followed by intravaginal
administration of MPLA, CCL28 or PBS 6 days after each
immunisation (Fig 2A). As observed previously [17], there was no
detectable mucosal IgA (Fig 2B) but detectable levels of mucosal
IgG (Fig 2C), sera IgA (Fig 2D) and IgG (Fig 2E) after
subcutaneous immunisation. It is of note that the sera IgA was 2
logs lower than seen after intranasal immunisation. Intravaginal
‘‘pull’’ stimulation with either MPLA or CCL28 had no effect on
levels of antigen specific antibody (IgA or IgG) in sera or mucosally
or B cell recruitment to the female genital tract (Fig 2F).
Comparing the subcutaneous immunised groups with the intra-
nasally immunised groups, we observe that intranasal immunisa-
tion gave greater mucosal levels of antibody and sera IgA, but
equivalent sera IgG to subcutaneous immunisation. Interestingly
intravaginal MPLA significantly increased the level of sera IgG in
the intranasal vaccine group but not the subcutaneous vaccine
group (Fig 1E and Fig 2E).
The observation that MPLA was effective at influencing vaginal
IgA responses following intranasal rather than systemic immuni-
sation fits with previous observations suggesting immunological
linkage between the upper respiratory and lower genital tract of
mice [20] and the preferential induction of IgA responses via
mucosal immunisation. Subsequent experiments were performed
to determine whether the timing of vaginal treatment with MPLA
following intranasal immunisation altered the effect on local
antibody responses. Peak plasmablast release into the circulation is
thought to occur approximately 7 days after immunisation
disappearing by day 14, while the accumulation of memory B
cells in the circulation occurs 14–28 days after immunisation [21].
To determine the differential impact on these B cell populations,
mice were immunised three times intranasally with a gp140 and
MPLA ‘‘prime’’ and intravaginal MPLA ‘‘pull’’ on either 0, 7 or
14 days after immunisation. Antigen specific IgA and IgG were
measured in sera and vaginally at seven day intervals. Intranasal
immunisation alone led to transient antigen specific IgA and IgG
in the sera after the third immunisation and IgA in the mucosal
lavage, no antigen specific IgG was detectable in the vaginal lavage
of any group at d56, 63 or 70. Administration of intravaginal
MPLA on the day of immunisation had no effect on IgA levels in
the vagina (Fig 3A) or the sera (Fig 3B) or serum IgG (Fig 3C)
compared to the control. Vaginal specific IgA responses were
significantly increased on day 63 after d14 ‘‘pull’’ stimulation
(Fig 3A, p,0.05), declining by day 70. Administration of
intravaginal MPLA on d7 after immunisation transiently en-
hanced serum specific IgA levels while administration on d14
significantly raised specific IgA in the sera on day 56 (Fig 3B,
p,0.05). Intravaginal administration of MPLA on day 14 also led
to a significant increase in antigen specific IgG in the sera after the
final intranasal immunisation at days 56, 63 and 70 (Fig 3C,
Figure 1. Intravaginal MPLA can boost local IgA responses after mucosal immunisation. BALB/c mice were immunised intranasally (IN)
with 10mg gp140+MPLA, 6 days later they received 10mg of CCL28 or MPLA or PBS control without antigen intravaginally (Ivag) (A). Gp140 specific IgA
and IgG were measured in vaginal lavage (B, C) or sera (D,E) at various timepoints after immunisation. Anti-gp140 and total IgA ASC were measured
by ELISPOT in pooled female genital tracts of mice at day 56 (F). Data points represent mean +/2 SEM of n= 8 animals from 1 experiment except
panel F where the bar represents mean of n= 3 pooled samples, *p,0.05, ** p,0.01, *** p,0.001 comparing MPLA and PBS groups, # p,0.05, ##
p,0.01, ### p,0.001 comparing MPLA and CCL28 groups.
doi:10.1371/journal.pone.0080559.g001
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p,0.01), with d7 administration leading to a slight increase at d63
and d70.
We have previously observed differences in the adjuvant effects
of different TLR agonists applied mucosally in mice [17]. We
wished to determine if there was a difference in effect with respect
to intravaginal stimulation of local antibody response. Mice were
immunised three times intranasally with the model HIV antigen
gp140 plus MPLA as a mucosal adjuvant and received intravag-
inal dosing with 10mg of either CpG (TLR9 agonist) or FSL-1
(TLR2/6 agonist) 7 days after immunisation. CpG appeared to
induce the highest level of specific IgA in the vagina, although due
to high variability this did not reach statistical significance (Fig 4A).
FSL-1 administration had no effect on local IgA responses. The
third intranasal immunisation led to increased levels of sera IgA
(Fig 4B) and IgG (Fig 4C), but there was no significant difference
between the ‘‘pull’’ TLR ligand used.
Discussion
In this study we wished to determine whether the local
administration of a stimulatory agent was able to increase local
antibody levels. We observed a modest, transitory increase in local
IgA with the TLR4 ligand MPLA, but no effect with the
chemokine CCL28. Boosting of local IgA only occurred when the
Figure 2. Intravaginal MPLA does not boost local IgA responses after systemic immunisation. BALB/c mice were immunised
subcutaneously (sc) with 10mg gp140+MPLA, 6 days later they received 10mg of CCL28 or MPLA or PBS control without antigen intravaginally (A).
Gp140 specific IgA and IgG were measured in vaginal lavage (B, C) or sera (D,E) at various timepoints after immunisation. Anti-gp140 and total IgA
ASC were measured by ELISPOT in pooled female genital tracts of mice at day 56 (F). Data points represent mean +/2 SEM of n = 8 animals from 1
experiment except panel F where the bar represents mean of n = 3 pooled samples.
doi:10.1371/journal.pone.0080559.g002
Figure 3. The timing of intravaginal MPLA application affects the boosting of local responses. BALB/c mice were immunised intranasally
with 10mg gp140+MPLA (black arrows), they received 10mg of MPLA alone intravaginally on d0, d7, or d14 post intranasal immunisation (grey arrows).
Gp140 specific IgA was measured in vaginal lavage (A) and gp140 specific IgA (B) or IgG (C) in sera at various timepoints after immunisation. Data
points represent mean +/2 SEM of n = 5 animals from 1 experiment, *p,0.05, **p,0.01, *** p,0.001 comparing MPLA d14 and control groups, #
p,0.05 comparing MPLA d7 and control groups.
doi:10.1371/journal.pone.0080559.g003
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mice were immunised intranasally and not when they were
immunised systemically. The timing of boost was important,
boosting on the day of immunisation had no effect on the local
titre, but boosting on d7 or d14 after immunisation increased the
local response and had a sustained effect on sera IgA and IgG
levels.
In contrast to the recruitment of T cells to the vaginal mucosa
with CCL9 and CCL10 after parenteral HSV immunisation [9],
we saw no significant increase in local antibody responses when
using the chemokine CCL28. One possibility for this is that
CCL28 may have not been the most effective chemokine to use,
whilst it has been shown to be important in homing to the
mammary gland [22] and the gut [23], homing requirements for
the vagina may be different. Other chemokines involved in the
recruitment of plasma cells or plasma blasts might have been more
effective. Possibilities include CXCL12 which engages CXCR4
and is involved in plasma cell retention in the bone marrow [24];
CXCL9, CXCL10 and CXCL11 which engage CXCR3 and lead
to the recruitment of plasma cells to inflamed sites [25]; CCL25
which engages CCR9 and is involved in the recruitment of IgA
plasma cells to the small intestine [23] and CCL19 which we have
shown can be effective when used as an adjuvant [14]. Previous
studies used a cocktail of chemokines and it may be that a single
chemokine is insufficient to recruit cells and B cells may require
additional signals for recruitment to mucosal sites than chemokine
alone for example up-regulation of integrins including a4b7 [26],
which have been shown to be more important in IgA cell
recruitment to the gut than CCL28 or CCL25 [27]. It is possible
that the dose of CCL28 used (10mg) was insufficient for the
recruitment of B cells, but the dose used was greater than the dose
of chemokine used in the HSV [9] or RSV [10] studies.
Appropriate formulation might enhance localized delivery of
CCL28, however greater doses of recombinant protein would
significantly reduce the potential translation of such an approach
to humans when accounting for differences in body mass and
would have significant cost implications for any potential prime-
pull vaccine strategy.
We did however see some effect of intravaginal boosting with
MPLA at day seven after immunisation. We hypothesize that the
mechanism by which this works is that the TLR ligands induce
local inflammation which leads to cellular recruitment to the
vagina. This is supported by the ELISPOT data which showed
that MPLA delivery increased numbers of both specific and non
specific IgA producing cells in the vagina. Previously it has been
shown that mice expressing a constitutively active form of TLR4
(the receptor for MPLA) express higher levels of CCL20, CCL28
and APRIL in intestinal epithelium [28]. Speculatively, this may
explain why TLR ligands were more effective than the application
of a single chemokine alone as they could induce a mixture of
factors. It was of interest that MPLA administration after
intranasal, but not subcutaneous immunisation significantly
increased serum antibody responses at the final immunisation.
This effect may be caused by residual inflammation caused by the
MPLA prior to subsequent immunisation. We hypothesize that the
MPLA is acting directly on B cells, priming them for antigen re-
exposure rather than acting on antigen presenting cells for two
reasons. Firstly the gap in timing between the MPLA administra-
tion and subsequent immunisation is seven days, during which
time it would be anticipated that the inflammation would have
resolved. Secondly, the MPLA administration is at a distal site to
the immunisation, so any activated antigen presenting cells would
need to be circulating to the immunisation site. The context of
immunisation is important and this data suggests that previous
TLR stimulation may alter the outcome of subsequent immuni-
sation. It was of note that MPLA administration only had an effect
on mucosally primed animals and not systemically primed
animals, suggesting that the context of vaccination is important
in B cell homing and circulation [12,17].
There are a number of caveats that may influence translation of
this approach to human vaccines. The first limitation is the modest
effect we observed in this study, but there may be differences going
into humans, especially due to the differences in TLR responses
between mice and humans. The second limitation is of a practical
nature – particularly as HIV vaccines are most relevant in
resource poor settings. Requiring individuals to return for a second
visit seven days after each immunisation would be extremely
restrictive, this could potentially be circumvented with home
administration of the boost – if formulated in a user friendly form.
But, there may be issues with the cultural acceptability of the
vagina for drug delivery. There is also a chance that inducing
immune activation in the vagina could increase the risk of
transmission [29]. Another issue is that this protection would only
be effective in controlling male to female vaginal transmission,
though it may be possible to boost immune responses with penile
Figure 4. The selection of TLR ligand affects the boosting of local responses. BALB/c mice were immunised intranasally with 10mg
gp140+MPLA (black arrows), they received 10mg of CpG or FSL-1 alone intravaginally on d7 post intranasal immunisation (grey arrows). Gp140
specific IgA was measured in vaginal lavage (A) and gp140 specific IgA (B) or IgG (C) in sera at various timepoints after immunisation. Data points
represent mean +/2 SEM of n = 5 animals from 1 experiment.
doi:10.1371/journal.pone.0080559.g004
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or rectal boosting. In conclusion whilst we observed a modest
increase of local and systemic antibody responses when MPLA was
used as a local boost we do not believe that this approach is
appropriate for future vaccine development.
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